Clinical intelligence platform
Delvant aggregates clinical evidence, synthesizes insights, and generates structured reports — so your team spends time on strategy, not data extraction.
KEY EFFICACY FINDING
OS 14.7m vs 9.6m
HR 0.66 · 95% CI [0.52–0.85] · p < 0.001
CR/CRi 36.7% vs 17.9% in unfit AML patients
Sample reports
Structured, evidence-graded clinical reports — built for medical affairs, clinical ops, and field teams.
BACKGROUND
AML patients unfit for intensive chemotherapy have historically poor outcomes. Venetoclax (BCL-2 inhibitor) + azacitidine targets apoptosis pathways, offering an active non-intensive regimen validated in a Phase III setting.
KEY EFFICACY FINDINGS
| Median OS | 14.7m vs 9.6m (HR 0.66, p<0.001) |
| CR / CRi Rate | 36.7% vs 17.9% |
| Event-Free Survival | 9.8m vs 7.0m |
SAFETY PROFILE
G3-4 neutropenia 42%, thrombocytopenia 45%, anemia 26%. Febrile neutropenia 42% vs 19% (control). Manageable with dose interruptions. No unexpected safety signals post-approval.
CLINICAL IMPLICATIONS
Standard of care for 1L unfit AML. OS benefit consistent across IDH1/2, FLT3, and TP53 subgroups. Open question: optimal treatment duration post-remission in fit-vs-unfit definitions.
KOL SENTIMENT SUMMARY
Palbociclib holds market leadership but KOL interest is shifting post-monarchE (abemaciclib adjuvant data). Ribociclib's OS benefit in premenopausal setting increasingly featured in EU congress presentations.
EVIDENCE COMPARISON
| Agent | PFS Benefit | OS Data |
|---|---|---|
| Palbociclib | +10.3m (PALOMA-2) | No OS benefit |
| Ribociclib | +12.8m (MONALEESA-7) | OS confirmed (premenop.) |
| Abemaciclib | +7.2m (MONARCH-3) | monarchE IDFS benefit |
MSL TALKING POINTS
EVIDENCE GAPS
No validated predictive biomarker beyond HR+ status. Real-world comparative data limited by selection bias. No head-to-head RCT across all three agents in any setting.
DATA SOURCES
| KEYNOTE-158 | Phase II RCT (tumor-agnostic pivot) |
| Flatiron Health | n=1,842 (US real-world evidence) |
| NCDB 2018–2024 | National claims data |
| ClinicalTrials.gov | 47 active studies extracted |
EVIDENCE SYNTHESIS
RWE confirms RCT signal across 12 tumor types. ORR 34.3% (RCT) vs 28.1% (RWE) — expected attenuation in real-world population. Durable responses: median DOR not reached at 36-month follow-up. MSI-H testing rates remain suboptimal in community settings (51% vs 89% academic).
REGULATORY CONTEXT
First tumor-agnostic FDA approval in oncology (2017). EMA 2022. NCCN Category 1 across dMMR/MSI-H tumor types. Payer coverage broadly favorable with companion diagnostic requirement.
STRATEGIC IMPLICATIONS
The problem
Trial data sits across ClinicalTrials.gov, publications, conference abstracts, and internal databases. No single view. No structure. No synthesis.
Analysts spend days pulling data, formatting slides, and cross-referencing sources before any insight generation begins. That is not a medical affairs function.
By the time a competitive landscape report is complete, the landscape has shifted. Reactive intelligence is not intelligence — it is history.
MSLs, medical affairs, and clinical ops work from disconnected sources. Duplicated effort and inconsistent field messaging are the result.
The solution
Delvant is a clinical intelligence aggregation layer. It connects to clinical trial databases, validates and structures evidence, and generates audience-segmented reports — on demand.
Full trial extraction across ClinicalTrials.gov and RWE databases. Paginated, validated, structured — not sampled.
Every claim evidence-graded. Executive brief, MSL section with talking points, and BD strategic analysis — one report, three audiences.
Forward signals, competitive scans, and status monitoring so your team is never reactive.
Intelligence architecture
ClinicalTrials.gov · PubMed · RWE sources · Internal data
Evidence tier tagging · Claim validation · Competitive mapping
Clinical Summary · MA Insight · RWE Synthesis · Forward Signals
How it works
Define the compound, indication, or competitive landscape of interest. Delvant scopes the query and initiates full extraction across connected databases.
Every trial is extracted, paginated, and validated. Evidence is tiered. Competitive threats are mapped. Forward signals are flagged — no manual work.
Output: executive brief, MSL-ready section with talking points, and a strategic analysis. Optional custom engagement for deeper scope.
Use cases by role
Example output
"CDK4/6 inhibitor landscape for HR+/HER2- BC — 3 agents, 12 trials, evidence-tiered with MSL talking points. Delivered in 48h."
Example output
"47 active dMMR/MSI-H trials across 12 indications — phase distribution, enrollment status, and endpoint comparison in one structured report."
Example output
"Venetoclax + Aza vs decitabine — evidence comparison with AML HCP objection scripts and 6 forward signals from active Phase II programs."
Engagement options
No public pricing. All engagements are scoped to your specific intelligence need.
30-minute live walkthrough. See a real intelligence report generated for your compound or indication — no slides, just output.
Free · No commitment
Request DemoDelvant generates a structured clinical intelligence report for one compound, indication, or competitive landscape. Fixed scope. Delivered within 5 business days.
Paid pilot · Scoped engagement
Request PilotMulti-report engagement for teams requiring ongoing intelligence across a portfolio. Includes executive summaries, MSL sections, and forward signals monitoring.
Enterprise · Custom scoping call
Contact usSpecific question, custom scope, or strategic discussion. Contact directly to explore whether Delvant fits your team's intelligence needs.
Open · Response within 24h
Email usGet started
Book a 30-minute demo. We will show you a live intelligence report for your compound or indication — no slides, no deck, just output.
No commitment. No pricing pressure. Just clinical intelligence.